This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Yossi Ben Shalom was appointed as a Director at BrainsWay on December 2018.
Mr. Ben Shalom is a co-founder of D.B.S.I, a private investment company specializing in investments in mature companies that are positioned globally for high growth or built for vast expansion through M&As.
As such, Mr. Ben Shalom serves as the Chairman of Pointer Telocation Ltd. (Nasdaq:PNTR), Rada (Nasdaq: RADA) and Shagrir Group Car Services Ltd. (TASE: SHGR), The 8 Note Production & Distribution Ltd., Car 2 Go Ltd., Matzman Et Merutz Milenum
He also serves as a director at Taldor Computer Systems (1986) Ltd. (TASE: TALD), Eldan Cargo Ltd., Ltd.
Mr. Ben Shalom was formerly Vice President of Koor Holdings (NASDAQ:KOR), and served as the CFO of Tadiran Ltd. Mr. Ben Shalom was an active director in numerous boards, such as NICE Systems, Machteshim Agan, Bank Klali, M-systems, and others.
Mr. Ben Shalom holds a BA in Economics and an MA in Business Administration both from Tel Aviv University.